Woman takes on 70 charity challenges in two years
A Cornish woman has spent almost two years completing 70 challenges to raise money for Multiple Sclerosis (MS) in a tribute to her mum who died with the condition.
Pippa Marshall, from Wadebridge, is now preparing for her biggest task yet; walking, cycling and swimming the 31-mile (50km) length of the River Camel.
Her mother Carol was diagnosed with MS when she was aged 19 and about to get married. As she gradually lost her mobility, Pippa became her carer.
Ms Marshall said: "My purpose is to honour Mum's memory and highlight the gift of movement that able bodied people take for granted."
MS is a debilitating neurological condition affecting the brain and spinal cord.
It causes severe pain, fatigue, cognitive issues and vision problems.
According to NHS England, more than 150,000 people in the UK are living with the condition.
The River Camel challenge includes walking 12 miles (20km) from its source above Camelford to Wenford on the Camel Trail where Ms Marshall will cycle another 12 miles to Wadebridge and then swim another six miles (10km) to Padstow.
Ms Marshall said it was a particularly personal challenge.
"Mum grew up in Grogley and went to school in Nanstallon, where she is now buried," she said.
"I grew up in Wadebridge so the River Camel has always been there in one way or another, linking us past and present.
"I am trying to train as I am a 50-year-old, unfit woman but have a lot of determination."
She said all of her 70 challenges had been inspired by her mother's determination despite her illness.
"Mum was housebound for approximately 10 years and ended up with epilepsy too.
"She suffered so much and her world became so small. I have always found it hard to deal with how sorrowful the whole thing was.
"She never complained, she was always bright and cheerful and the thing that she said was that there is always someone worse off than yourself.
"So this has all been about telling the world that Mum - Carol Marshall existed."
More news stories for Cornwall
Listen to the latest news for Cornwall
Carol Marshall died aged 63 and her daughter decided to take on her 70 challenges to mark what would have been her mum's 70th birthday.
Other activities have included hang gliding, swimming around St Michael's Mount, singing in public, entering cake competitions using her mum's cookbook and entering her mother's artwork into local events.
Her big 50km challenge, when she will be supported by Open Water Devon, is set to take place on 22 June.
Follow BBC Cornwall on X, Facebook and Instagram. Send your story ideas to spotlight@bbc.co.uk.
'My mum's MS inspires me to run ultra marathons'
Man takes on five-year £500k charity river challenge
NHS England - Multiple sclerosis
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 hours ago
- Yahoo
Access Free Educational Videos and Webinars Provided by the Multiple Sclerosis Association of America
CHERRY HILL, N.J., June 25, 2025 /PRNewswire/ -- The Multiple Sclerosis Association of America (MSAA) is pleased to provide vital services and resources to individuals affected by MS, their families, and care partners. One of the many MSAA resources available is the Multiple Sclerosis Information (MSi) Video Library. This extensive library features a growing collection of content including webinars, educational videos, and recorded programs that are invaluable to the MS community. MSAA's webinars and videos cover pressing topics, which include understanding MS, lifestyle challenges, symptom management, health equities and diversity, as well as other vital topics. These resources provide an immeasurable wealth of knowledge and empowerment, accessible right from the comfort of viewers' homes. With MSAA's mission of Improving Lives Today, we strive to ensure the MS community feels supported and equipped with educational resources to help with navigating their journey with MS. "Knowledge is power, especially when living with a complex condition such as multiple sclerosis," says Gina Ross Murdoch, President and CEO of MSAA. "Our video library is designed to deliver accessible, high-quality information from trusted sources, helping people to better understand and manage an MS diagnosis." This on-demand video library is optimized for both mobile and desktop devices and includes transcripts of programs to ensure accessibility to all viewers. Users can easily browse by category to find content tailored to their specific interests and needs. To view MSAA's MSi Video Library, please visit MSAA's website at For more information regarding MSAA's Multiple Sclerosis Information Video Library, please contact Diana Cruz-Beniquez, Manager of Public Relations & Engagement, at (800) 532-7667, ext. 103, or via email at dcruz@ About MSAA The Multiple Sclerosis Association of America (MSAA) is a national nonprofit organization and leading resource for the entire MS community, improving lives today through vital services and support. MSAA provides numerous programs and services at no cost including: a Helpline with trained specialists; award-winning publications, including, The Motivator magazine; educational videos, webinars, and research updates; a mobile phone app, My MS Manager™; safety and mobility equipment products; cooling accessories for heat-sensitive individuals; My MSAA Community, a peer-to-peer online support forum; MS Conversations blog; a clinical trial search tool; podcasts; and more. For additional information, please visit or call (800) 532-7667. About Multiple Sclerosis Multiple sclerosis (MS) is a disease of the central nervous system (CNS), which consists of the brain, optic nerves, and spinal cord. MS damages or destroys the protective covering (known as myelin) surrounding the nerves of the CNS and can potentially injure the nerves as well. This damage causes reduced communication between the brain and nerve pathways. Common MS symptoms include visual problems, overwhelming fatigue, difficulty with balance and coordination, depression and cognitive issues, and various levels of impaired mobility. The prevalence of multiple sclerosis is estimated at nearly one million people nationwide and most people with MS are diagnosed between the ages of 20 and 50. Researchers continue to learn more as they look for both a cause and a cure. View original content to download multimedia: SOURCE Multiple Sclerosis Association of America 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
Yahoo
a day ago
- Yahoo
PDS Health Raises Over $1.9 Million Through Smile Generation to Support charity: water's Clean Water Projects
Campaign proceeds will fund clean, safe drinking water for over 48,000 people in Ethiopia. HENDERSON, Nev., June 24, 2025 /PRNewswire/ -- PDS Health®, a leading provider of integrated healthcare support services, announced that its 2025 campaign for charity: water raised over $1.9 million ― its most successful to date. Through its consumer brand, Smile Generation®, PDS Health mobilized its nationwide network of dental and medical practices and the patients they serve to support clean water access for underserved communities. The proceeds will fund long-term, community-owned water systems in Ethiopia, benefiting more than 48,000 people. Smile Generation is a key extension of PDS Health's mission to advance whole-person health. In addition to connecting patients with trusted local dentists and offering accessible financing, Smile Generation plays an essential role in educating patients about the Mouth-Body Connection®, or the link between oral health and overall health. Through this campaign, Smile Generation-trusted practices also raised awareness of the fundamental role clean water plays in sustaining health and highlighted the particular benefit it will have on young women and girls, who spend the majority of their time traveling to get clean water for their families. "Access to clean water is essential to health. This campaign reflects our broader mission to improve lives through better access to basic needs," said Stephen E. Thorne IV, Founder and CEO of PDS Health. "Much like PDS Health's mission to improve the overall health of our patients through better access to quality care, charity: water is similarly committed to making a positive impact on the health of people it serves. We're proud to continue this partnership that will improve the long-term health of thousands of people around the globe." Millions of people around the world still lack basic access to clean, safe drinking water. In many rural communities, women and girls walk for hours each day to collect water for their families, limiting their education, health and economic opportunities. Since 2006, charity: water has funded water, sanitation, and hygiene (WASH) programs for rural communities, serving more than 20.2 million people in 29 countries across Africa, Asia, Central and South America. PDS Health has partnered with charity: water since 2009. Over 16 years, the organization has raised more than $12.3 million, supporting over 500 water projects in six countries and bringing clean water to an estimated 345,000 people. "We've been continually blown away by the dedication to our mission from our friends at Smile Generation and PDS Health over the last decade and a half," said Scott Harrison, CEO of charity: water. "This year's campaign was the single-most successful peer-to-peer fundraiser by a brand partner in the history of charity: water ― raising nearly $2 million to bring clean water to an estimated 48,905 people!" To learn more about how PDS Health and Smile Generation support healthier, happier communities, visit About PDS HealthPDS Health® continues the journey started by Pacific Dental Services® in 1994, with a vision to redefine health care through the integration of dental and medical services. Its approach, centered on the connection between oral health and overall health, aims to create healthier, happier patients and set new benchmarks in the healthcare industry. As a leading provider of integrated healthcare support, the company delivers a broad spectrum of services to dental, dental specialties, and medical providers, enhancing operations and care delivery for clinicians across the U.S. For more information about PDS Health and its vision, visit About Smile Generation Smile Generation® connects patients to Smile Generation-trusted dentists who are dedicated to providing an exceptional patient experience and advanced clinical care. Smile Generation also provides financial choices for patients and education about the connection between oral health and overall health (The Mouth-Body Connection®). The Smile Generation network spans over 1,000 dental offices in 24 states. Smile Generation-trusted offices are supported by PDS Health®. For more information, visit About charity: water charity: water is a nonprofit organization bringing clean and safe drinking water to people around the world. With powerful storytelling and a radically transparent model that ensures 100% of every public donation funds clean water, charity: water has mobilized supporters from more than 150 countries to help end the water crisis. They work exclusively with experienced local partners to build sustainable, community-owned water projects and prove each one with innovative technology. Since 2006 in New York and 2017 in London, charity: water has funded over 186,000 water projects in 29 countries to help more than 20.2 million people get access to clean water, hygiene, and improved sanitation. For more information, visit The Mouth-Body Connection® and Smile Generation® are registered trademarks of PDS Health. View original content to download multimedia: SOURCE PDS Health Sign in to access your portfolio
Yahoo
2 days ago
- Yahoo
Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis
– At Week 144, 92.3% of Patients Remained Free of 12-Week Confirmed Disability Worsening (CDW) With 92.7% Remaining Free of 24-Week CDW – – Vidofludimus Calcium Continues to Demonstrate Favorable Safety and Tolerability Profile; Long-Term Data Now Available up to 5.5 Years – NEW YORK, June 24, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today reported new long-term open-label extension (OLE) data from its phase 2 EMPhASIS trial of lead asset, orally available nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), in patients with relapsing-remitting multiple sclerosis (RRMS). "It is meaningful to see that patients treated with vidofludimus calcium during the OLE period of our phase 2 EMPhASIS trial in RRMS experienced a low rate of confirmed disability worsening (CDW) events, as measured by the Expanded Disability Status Scale (EDSS). This data, representing approximately 952 treatment years, further underlines our belief that vidofludimus calcium holds great potential to effectively manage the disease, help preserve neurological function, allow patients to maintain independence and improve long-term quality of life," stated Andreas Muehler, M.D., M.B.A., Chief Medical Officer of Immunic. The data at week 144 showed that 92.3% of patients remained free of 12-week CDW, and 92.7% free of 24-week CDW. A total of 29 CDW events were confirmed at 12 weeks following the trigger event through week 144. Of these, 44.8% were associated with relapse-associated worsening (RAW), while only 13.8% were associated with progression independent of relapse activity (PIRA). Additionally, the cumulative data available from the EMPhASIS OLE period, thus far, further reinforces the favorable safety and tolerability profile of vidofludimus calcium, showing low discontinuation rates and low rates of treatment-emergent and serious adverse events. Importantly, no new safety signals have emerged during treatment durations up to 5.5 years. "This new data from the OLE period is very encouraging and continues to corroborate the prior strong results we observed in our phase 2 EMPhASIS trial in RRMS," stated Daniel Vitt, Ph.D., Chief Executive Officer of Immunic. "The ability to maintain remarkably low rates of disability progression is among the most important unmet needs in relapsing MS despite the availability of multiple anti-inflammatory drugs approved for the treatment of MS relapses. By delaying disease progression, MS patients maintain greater independence, face a lower burden in managing their symptoms and experience more favorable long-term outcomes." "Additionally, previously announced data across our multiple sclerosis (MS) program, including from the EMPhASIS trial as well as our recent top-line data from the phase 2 CALLIPER trial in progressive multiple sclerosis, has further highlighted vidofludimus calcium's potential to slow disease progression in MS and substantiated its neuroprotective capabilities through the activation of the Nurr1 target. As a reminder, despite 30-years of commercially available MS treatments, slowing and preventing disease progression still remains a critical unmet need. Based on the data we have generated, to date, we continue to believe that vidofludimus calcium, with its combined neuroprotective, anti-inflammatory and anti-viral effects as well as its established, highly favorable safety and tolerability profile, could represent a unique new oral therapy targeted to the complex pathophysiology of MS." The phase 2 EMPhASIS trial was an international, multicenter, double-blind, placebo-controlled, randomized, parallel-group study, designed to assess the efficacy and safety of vidofludimus calcium in patients with RRMS. The trial randomized 268 RRMS patients and included a 24-week blinded main treatment period testing 10, 30 and 45 mg of vidofludimus calcium and placebo. The trial achieved both primary and key secondary endpoints with high statistical significance and showed a favorable safety and tolerability profile similar to placebo. The trial includes an optional OLE period for up to 9.5 years to evaluate long-term safety and tolerability of vidofludimus calcium. Of the 268 patients that started the double-blind main treatment period, 254 patients continued in the OLE period. Patients were initially given either 30 mg or 45 mg of vidofludimus calcium once-daily, following which all patients received 30 mg of vidofludimus calcium once-daily. At the time of data cutoff on January 14, 2025, 182 patients (71.6% of patients starting OLE) were evaluated up to week 144, which translates into approximately 952 overall treatment years. About Vidofludimus Calcium (IMU-838)Vidofludimus calcium is an orally administered investigational small molecule drug being developed for chronic inflammatory and autoimmune diseases, currently in late-stage clinical trials for multiple sclerosis (MS). Uniquely, vidofludimus calcium's first-in-class, dual mode of action combines neuroprotective, anti-inflammatory and anti-viral effects to target the complex pathophysiology of MS. As a selective immune modulator, it activates the neuroprotective transcription factor, nuclear receptor-related 1 (Nurr1), which provides direct and indirect neuroprotective effects. Additionally, vidofludimus calcium achieves anti-inflammatory and anti-viral effects through highly selective inhibition of the enzyme dihydroorotate dehydrogenase (DHODH). Vidofludimus calcium is currently being evaluated in phase 3 clinical trials for the treatment of relapsing MS. In a phase 2 clinical trial, it has shown therapeutic activity in relapsing-remitting MS patients, significantly reducing brain lesions and demonstrating encouraging results in reducing confirmed disability worsening. Additionally, vidofludimus calcium has demonstrated clinical benefits in progressive MS patients by showing substantial reductions in confirmed disability worsening and thalamic brain volume in a phase 2 clinical trial. To date, vidofludimus calcium has been exposed to approximately 2,700 individuals and has shown an attractive pharmacokinetic, safety and tolerability profile. Vidofludimus calcium is not yet licensed or approved in any country. About Immunic, Inc. (Nasdaq: IMUX) is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 clinical trials for the treatment of relapsing multiple sclerosis, for which top-line data is expected to be available by the end of 2026. It has already shown therapeutic activity in phase 2 clinical trials in patients suffering from relapsing-remitting multiple sclerosis and progressive multiple sclerosis. Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor related 1 (Nurr1) activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease as well as inflammatory bowel disease, Graft-versus-Host-Disease and weight management. IMU-381, which currently is in preclinical testing, is a next generation molecule being developed to specifically address the needs of gastrointestinal diseases. For further information, please visit: Cautionary Statement Regarding Forward-Looking StatementsThis press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Immunic's development programs and the targeted diseases; the potential for vidofludimus calcium to safely and effectively target diseases; preclinical and clinical data for vidofludimus calcium; the timing of current and future clinical trials and anticipated clinical milestones; the nature, strategy and focus of the company and further updates with respect thereto; and the development and commercial potential of any product candidates of the company. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, increasing inflation, tariffs and macroeconomics trends, impacts of the Ukraine – Russia conflict and the conflict in the Middle East on planned and ongoing clinical trials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, any changes to the size of the target markets for the Company's products or product candidates, the protection and market exclusivity provided by Immunic's intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned "Risk Factors," in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 31, 2025, and in the company's subsequent filings with the SEC. Copies of these filings are available online at or Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all of the contents of this press release. Contact Information Immunic, BreuVice President Investor Relations and Communications+49 89 2080 477 US IR ContactRx Communications GroupPaula Schwartz+1 917 633 7790immunic@ US Media ContactKCSA Strategic CommunicationsCaitlin Kasunich+1 212 896 1241ckasunich@ View original content to download multimedia: SOURCE Immunic, Inc.
